問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Gastroenterological Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital
National Health Research Institutes

Division of Hematology & Oncology

更新時間：2023-09-19

沈延盛Shan, Yan-Shen
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • ncku013@hotmail.com

Recruiting Trial

57Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

沈延盛

List

114Cases

2018-10-01 - 2021-03-31

Phase I

Completed
Phase 1 Study of Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

  • Condition/Disease

    Solid tumors

  • Test Drug

    nal-IRI

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

白禮源
China Medical University Hospital-Taipei

未分科

2022-01-01 - 2026-03-31

Phase II

Active
A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    CVM-1118 膠囊 (又名 CVM-1118 速放膠囊 )

Participate Sites
6Sites

Recruiting6Sites

2017-06-08 - 2019-12-31

Phase I

Completed
Phase 1 Study of ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers.

  • Condition/Disease

    Advanced Solid Cancers

  • Test Drug

    ADI-PEG20

Participate Sites
1Sites

Terminated1Sites

2015-01-01 - 2016-11-30

Phase I

Completed
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies

  • Condition/Disease

    Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors

  • Test Drug

    ADI-PEG 20

Participate Sites
1Sites

Terminated1Sites

2019-01-01 - 2025-12-31

Phase I

Completed
Phase 1-2 Study of ADI PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular carcinoma

  • Test Drug

    ADI-PEG20

Participate Sites
13Sites

Terminated12Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2024-03-01 - 2026-12-31

Phase I

臨床一期、開放性、劑量探索之試驗，旨在評估LBL-01注射劑用於晚期實體腫瘤患者安全性、耐受性、藥物動力學與初步療效

  • Condition/Disease

    晚期實體腫瘤

  • Test Drug

    LBL-01 Injection

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2013-03-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-03-01 - 2020-12-31

Others

A PHASE Ib/III, OPEN-LABEL, MULTICOHORT, MULTICENTER, STUDY EVALUATING THE EFFICACY AND SAFETY OF RO6958688 PLUS ATEZOLIZUMAB, WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

  • Condition/Disease

    METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

  • Test Drug

    RO6958688、Tecentriq、Onivyde、Leucovorin、Abraxane、Fluorouracil (5-FU)、Gemcitabine

Participate Sites
3Sites

Terminated3Sites

2021-02-01 - 2027-12-31

Phase II

Open-label, multi-cohort, Phase 2 trial, evaluating the efficacy and safety of SAR408701 in patients with CEACAM5-positive advanced solid tumors

  • Condition/Disease

    solid tumors

  • Test Drug

    SAR408701

Participate Sites
3Sites

Recruiting3Sites

2009-05-01 - 2009-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 4 5 6 7 8 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB